Concepedia

Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease

Ningning Wan, Yoshihide Fujisawa, Hideki Kobara, Tsutomu Masaki, Daisuke Nakano, Asadur Rahman, Akira Nishiyama

Hypertension Research · 2020 · 46 citations · 28 references

DOIFull text

Open access

Concepts

References

28

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

Robert Ćhilton, I. Tikkanen, Christopher P. Cannon et al. · Diabetes Obesity and Metabolism · 2015 · 510 citations · Full text

, , +17

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

Christoph Wanner, John M. Lachin, Silvio E. Inzucchi et al. · Circulation · 2017 · 471 citations · Full text

, , +17

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study

Muhammad Abdul‐Ghani, Stefano Del Prato, Robert Ćhilton et al. · Diabetes Care · 2016 · 301 citations · Full text

, , +17

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

Julio Rosenstock, Ante Jelaska, Cordula Zeller et al. · Diabetes Obesity and Metabolism · 2015 · 257 citations · Full text

, , +14

Twenty-Four-Hour Blood Pressure–Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension

Kazuomi Kario, Kenta Okada, Mitsutoshi Kato et al. · Circulation · 2019 · 249 citations · Full text

, , +17